Johnson & Johnson Experimental Immunotherapy Combination Reduces Prostate Cancer PSA Levels in Early Trial
Johnson & Johnson (JNJ) reported positive preliminary results from an early-stage clinical trial evaluating a new immunotherapy combination for prostate cancer. In the study, 11 out of 15 patients receiving the recommended regimen experienced at least a 50% reduction in Prostate-Specific Antigen (PSA), a key blood marker used to monitor cancer activity. The treatment utilizes a combination therapy involving pasritamig. While the patient cohort is small, the significant reduction in PSA levels provides an early signal of efficacy for this experimental approach. Further clinical testing will be required to validate these findings and determine long-term outcomes.
Tickers: $JNJ
Topics: clinical trials immunotherapy prostate cancer
Read the full article at Seeking Alpha
Part of the story J&J prostate cancer combination lowers PSA in small early study (2 articles)